Literature DB >> 22361927

Tuberculosis in childhood.

Delane Shingadia1.   

Abstract

There has been a recent global resurgence of tuberculosis (TB) fuelled by HIV infection and migration. Childhood TB represents a sentinel event in the community, suggesting recent transmission from an infectious adult. The diagnosis of TB in children is based on chest X-ray, tuberculin skin testing and mycobacterial staining/culture, although the diagnostic yield from these investigations is often lower than in adults. Newer diagnostic tests are being developed and may improve the diagnostic yield in childhood TB. Treatment of TB in children is similar to adults in that short-course multidrug treatment has been adopted as standard therapy in many national TB programmes. Compliance is a major determinant of the success of drug treatment and directly observed therapy has been adopted as a key component of TB treatment programmes. Although uncommon in children, multidrug-resistant TB is also increasing and treatment often involves longer courses of therapy with second-line drugs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22361927     DOI: 10.1177/1753465812436662

Source DB:  PubMed          Journal:  Ther Adv Respir Dis        ISSN: 1753-4658            Impact factor:   4.031


  2 in total

1.  Evaluation of Chest X-ray and Thoracic Computed Tomography in Patients with Suspected Tuberculosis.

Authors:  Mehmet Sait Durmus; Ismail Yildiz; Murat Sutcu; Muhammet Bulut; Muhammet Ali Varkal; Furkan Ubeydullah Ertem; Ayse Kilic; Fatma Oguz; Emin Unuvar; Ensar Yekeler
Journal:  Indian J Pediatr       Date:  2015-12-03       Impact factor: 1.967

2.  Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis.

Authors:  Thomas Pouplin; Nguyen Duc Bang; Pham Van Toi; Pham Nguyen Phuong; Nguyen Huy Dung; Tran Ngoc Duong; Maxine Caws; Guy E Thwaites; Joel Tarning; Jeremy N Day
Journal:  BMC Infect Dis       Date:  2016-04-02       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.